Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve Replacement
HANGZHOU, China, Dec. 8, 2021 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatm...
Venus Medtech Appoints Professor Martin B. Leon as Global Principal Investigator of Its New-Generation RDN System
HANGZHOU, China, July 28, 2021 /PRNewswire/ -- On July 27, 2021, Venus Medtech ( Hangzhou) Inc. ("Venus Medtech") (stock code: 2500.HK), a leading provider of comprehensive interventional heart valve therapy solutions inChina, and its controlling subsidiary Renaly Ltd., announced that Professor...
Venus Medtech Taps into Surgical Heart Valve Market by Cooperating with Haoyue Group to Develop the Business of High-end Biomaterial Medical Devices
HANGZHOU, China, Sept. 10, 2020 /PRNewswire/ -- The leading transcatheter heart valve medical device player inChina - Venus Medtech (Hangzhou) Inc. ("Venus Medtech" or the "Company", together with its subsidiaries, the "Group", stock code: 2500) andJilin Changchun Haoyue Halal Meat Co., Ltd ("Hao...
Venus Medtech to Partner with Pi-Cardia to Bring its Leaflex(TM) Aortic Valve Technology to China
HANGZHOU, China and REHOVOT, Israel, July 14, 2020 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (stock code: 2500.HK), the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating...
Venus Medtech and Opus Medical Therapies, LLC Announce Partnership for Transcatheter Mitral Valve Replacement (TMVR) and Transcatheter Tricuspid Valve Replacement (TTVR) in Greater China Market
HANGZHOU, China and ATLANTA, May 2, 2020 /PRNewswire/ -- Venus Medtech (Hangzhou ) Inc. ("Venus Medtech" or the "Company", together with its subsidiaries, the "Group", stock code: 2500), the leading Chinese transcatheter heart valve company and Opus Medical Therapies, LLC, a medical device company...
Venus Medtech Announces the Addition of Two Cardiovascular Experts to Their Advisory Team
HANGZHOU, China, Jan. 20, 2020 /PRNewswire/ -- The leading transcatheter heart valve medical device player inChina - Venus Medtech (Hangzhou) Inc. ("Venus Medtech" or the "Company", stock code: 2500.HK), today is pleased to announce the appointment of two new cardiovascular experts to its advisor...
